Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$471.85 USD

471.85
1,399,486

+1.77 (0.38%)

Updated Aug 11, 2025 04:00 PM ET

After-Market: $472.00 +0.15 (0.03%) 5:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Accuray (ARAY) Earnings Beat in Q4, Gross Orders Rise Y/Y

by Zacks Equity Research

Accuray's (ARAY) flagship Radixact System drives Q4 results; overseas gains raise hope.

    Zacks Equity Research

    Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure

    by Zacks Equity Research

    Intuitive Surgical's (ISRG) impressive second-quarter 2018, strength in robotics and AI trends buoy optimism.

      Zacks Equity Research

      Hologic Launches Fluent Fluid Management System, Widens Suite

      by Zacks Equity Research

      Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.

        Zacks Equity Research

        Here's Why You Should Invest in Align Technology (ALGN) Now

        by Zacks Equity Research

        We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally.

          Zacks Equity Research

          AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology

          by Zacks Equity Research

          AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.

            Zacks Equity Research

            Wright Medical Strong Overseas, Back Order Issues Persist

            by Zacks Equity Research

            Wright Medical (WMGI) rides on recent approval of AUGMENT Injectable and a solid guidance for 2018; pricing pressure prevails.

              Zacks Equity Research

              Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm

              by Zacks Equity Research

              Medtronic's (MDT) recent launch of IN.PACT Admiral DCB in Japan is expected to boost the top line.

                Zacks Equity Research

                Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children

                by Zacks Equity Research

                Masimo's (MASI) SET pulse oximetry successfully identifies DS in children with high risk of OSA.

                  Zacks Equity Research

                  Inogen's Solid Europe Business Shapes Q2, Prospects Bright

                  by Zacks Equity Research

                  Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.

                    Zacks Equity Research

                    Bio-Rad (BIO) Banks on Blood Typing Market Amid Margin Woes

                    by Zacks Equity Research

                    Bio-Rad (BIO) actively expands portfolio for blood typing market; declining gross margin a concern.

                      Zacks Equity Research

                      Becton, Dickinson Global Foothold Strong, Recalls Rampant

                      by Zacks Equity Research

                      Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.

                        Zacks Equity Research

                        Has Intuitive Surgical (ISRG) Outpaced Other Medical Stocks This Year?

                        by Zacks Equity Research

                        Is (ISRG) Outperforming Other Medical Stocks This Year?

                          Zacks Equity Research

                          STERIS (STE) Q1 Earnings & Revenues Beat Estimates, Up Y/Y

                          by Zacks Equity Research

                          STERIS (STE) continues to gain from strength in all business segments in Q1.

                            Zacks Equity Research

                            Allscripts Sunrise Picked by UK's Maidstone and Tunbridge Wells

                            by Zacks Equity Research

                            Allscripts' (MDRX) Sunrise platform witnesses a suite of developments, fortifying the company's global foothold.

                              Zacks Equity Research

                              Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates

                              by Zacks Equity Research

                              Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.

                                Zacks Equity Research

                                OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2

                                by Zacks Equity Research

                                OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE; declining segmental revenues raise concern.

                                  Zacks Equity Research

                                  Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View

                                  by Zacks Equity Research

                                  Growth in the upper and lower extremity segments drives Wright Medical's (WMGI) Q2 results.

                                    Zacks Equity Research

                                    Bio-Rad (BIO) Tops Earnings and Revenue Estimates in Q2

                                    by Zacks Equity Research

                                    Bio-Rad's (BIO) solid growth in North America, China and Asia Pacific reflects strong international foothold in Q2.

                                      Zacks Equity Research

                                      CVS Health's (CVS) Q2 Earnings Beat Estimate, Margins Up

                                      by Zacks Equity Research

                                      CVS Health (CVS) reports strong Pharmacy Services revenues, benefiting from the upside in the specialty services. Year-over-year Retail/LTC comparisons are also encouraging.

                                        Zacks Equity Research

                                        BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Top

                                        by Zacks Equity Research

                                        A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.

                                          Zacks Equity Research

                                          Allscripts Gains From Strong Results in Q2, Competition Rife

                                          by Zacks Equity Research

                                          Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.

                                            Zacks Equity Research

                                            Penumbra (PEN) Q2 Earnings & Revenues Top Estimates, View Up

                                            by Zacks Equity Research

                                            Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q2.

                                              Zacks Equity Research

                                              Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance

                                              by Zacks Equity Research

                                              Inogen (INGN) puts up solid segmental show in Q2; international sales surge.

                                                Zacks Equity Research

                                                Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View

                                                by Zacks Equity Research

                                                Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.

                                                  Zacks Equity Research

                                                  Teleflex (TFX) Q2 Earnings Top, Sales Lag, '18 View Bearish

                                                  by Zacks Equity Research

                                                  Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.